What question did this study set out to answer?

The study aims to evaluate the survival outcomes of alemtuzumab induction compared to ATG in septuagenarians undergoing kidney transplantation.

March 7, 20261 citations

Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation.

Q: What does this research mean for the field?

Alemtuzumab induction is associated with worse survival outcomes compared to ATG in septuagenarians undergoing deceased donor kidney transplantation. Novelty: ClaimNovelty.CONTRADICTORY. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

View Full Paper

DHDavid I HarrimanUniversity of British Columbia ANAlex NgUniversity of British Columbia AFAlan C. FarneyAtrium Health Wake Forest Baptist

Key Points

The study aims to evaluate the survival outcomes of alemtuzumab induction compared to ATG in septuagenarians undergoing kidney transplantation.
Compared survival outcomes of patients receiving alemtuzumab versus those receiving ATG induction.
Analyzed data on elderly patients undergoing deceased donor kidney transplantation.
Assessed the impact of triple maintenance immunosuppression on outcomes.
ATG induction showed improved survival outcomes compared to alemtuzumab.
Findings suggest that alemtuzumab may not be the preferred choice for elderly kidney transplant patients.
Caution is advised when using alemtuzumab in this demographic.

Abstract

ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider